^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Salivary Gland Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastric Cancer)
    New
    Excerpt:
    Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

    Excerpt:
    ...- Patients must have a histologically proven Her2 overexpressing malignancy as determined by any standardized assay currently in clinical use...
    Trial ID:
    NCT00004074
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Head Neck Oncol
    Title:

    Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine

    Excerpt:
    Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid. He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution. Continued treatment has resulted in maintenance of disease control for over 2 years.
    Secondary therapy:
    capecitabine + zoledronic acid
    DOI:
    10.1186/1758-3284-2-12